{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-058520","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.352407+00:00","generated_at":"2026-06-15T06:19:21.619476+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"AbbVie shareholders elect directors, ratify auditor, approve say-on-pay; supermajority amendment fails","bullets":["Class II directors Alpern, Meyer, Waddell elected with 1.14B, 1.25B, and 1.21B votes respectively.","Shareholders ratified Ernst & Young as auditor for 2023 with 1.49B votes for vs 18.7M against.","Advisory vote on executive compensation passed with 1.14B for vs 109.3M against.","Management proposal to eliminate supermajority voting failed (1.24B for, 1.29M against; needed supermajority).","Stockholder proposal for simple majority voting approved with 668.5M for vs 581.3M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-058520","json":"https://secwatch.observer/filing/0001104659-23-058520.json","markdown":"https://secwatch.observer/filing/0001104659-23-058520.md","text":"https://secwatch.observer/filing/0001104659-23-058520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/tm2315162d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:19:21.619476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"001d06516f9b04976c54f1de1a1134a42b1f7734","claim":"AbbVie Inc. shareholders approved Election of Class II Directors at the 2023-05-05 meeting.","evidence_excerpt":"(1) The stockholders elected AbbVie’s Class II Directors with terms expiring in 2026, as follows: Name For Against Broker Non-Votes Robert J. Alpern 1,142,062,843 20,689,813 251,363,568 Melody B. Meyer 1,247,333,998 4,243,832 251,363,568 Frederick H. Waddell 1,208,836,612 14,319,844 251,363,568","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"055d94b16eb0d8bb3e384eb6ca16cde31f46d9e6","claim":"AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on lobbying at the 2023-05-05 meeting.","evidence_excerpt":"(7) The stockholders did not approve a stockholder proposal to issue an annual report on lobbying, as follows: For Against Abstain Broker Non-Votes 448,957,091 787,145,991 20,487,503 251,363,568","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"0b2d8aab99bc7ca05fac918f5337996b4993bdeb","claim":"AbbVie Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2023-05-05 meeting.","evidence_excerpt":"(3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2023 annual meeting, as follows: For Against Abstain Broker Non-Votes 1,137,389,680 109,281,658 9,919,247 251,363,568","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"2139e22fa3aaaaf8d2f1dc2c47a78084b0cabda3","claim":"AbbVie Inc. shareholders rejected Amendment of certificate of incorporation to eliminate supermajority voting at the 2023-05-05 meeting.","evidence_excerpt":"(4) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,241,106,832 11,289,016 4,194,737 251,363,568","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"48d293b05f72abd641a16d625e776da8e568dd1a","claim":"AbbVie Inc. shareholders approved Stockholder proposal to implement simple majority voting at the 2023-05-05 meeting.","evidence_excerpt":"(5) The stockholders approved a stockholder proposal to implement simple majority voting, as follows: For Against Abstain Broker Non-Votes 668,497,335 581,300,391 6,792,859 251,363,568","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"88789d41bdaf019544b897e5b09224b63727d35f","claim":"AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on political spending at the 2023-05-05 meeting.","evidence_excerpt":"(6) The stockholders did not approve a stockholder proposal to issue an annual report on political spending, as follows: For Against Abstain Broker Non-Votes 187,829,409 1,052,110,624 16,650,552 251,363,568","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"8db2034f20d8b896c74e4962c65f53a45b4b6047","claim":"AbbVie Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2023 at the 2023-05-05 meeting.","evidence_excerpt":"(2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2023, as follows: For Against Abstain 1,486,053,290 18,676,821 3,224,042","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"c0299137e08ec477d86c5e0e1d662364451de8dd","claim":"AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on patent process at the 2023-05-05 meeting.","evidence_excerpt":"(8) The stockholders did not approve a stockholder proposal to issue an annual report on patent process, as follows: For Against Abstain Broker Non-Votes 363,777,601 867,061,281 25,751,703 251,363,568","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-05-05"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}